In the second period (from 2006 to 2016), there was an increasing trend in the annual publication volume, which may be attributed to the FDA approval of ranolazine as a drug for treating chronic angina in 2006.
1
—
—
In the second period (from 2006 to 2016), there was an increasing trend in the annual publication volume, which may be attributed to the FDA approval of ranolazine as a drug for treating chronic angina in 2006.